MRK · News · 20260921N

Product Launch and Transition

Merck & Co., Inc. · 2026-09-21 · Importance 38 · Surprise 60

Japan’s Ministry of Health, Labor and Welfare approved KEYTRUDA QLEX, a subcutaneous formulation combining pembrolizumab and berahyaluronidase alfa-pmph. The approval covers all KEYTRUDA indications already approved in Japan. The product is planned to be marketed in Japan under the KEYJECT trademark, expanding administration options for Merck’s anti-PD-1 therapy.

Key facts

• In Japan, KEYJECT® is the planned trademark for KEYTRUDA QLEX for subcutaneous injection. source